Published in

Public Library of Science, PLoS ONE, 11(15), p. e0242184, 2020

DOI: 10.1371/journal.pone.0242184

Links

Tools

Export citation

Search in Google Scholar

Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients

Journal article published in 2020 by Daniel Camprubí, Alex Almuedo-Riera ORCID, Helena Martí-Soler ORCID, Alex Soriano, Juan Carlos Hurtado ORCID, Carme Subirà ORCID, Berta Grau-Pujol ORCID, Alejandro Krolewiecki ORCID, Jose Muñoz
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Ivermectin has recently shown efficacy against SARS-CoV-2 in-vitro. We retrospectively reviewed severe COVID-19 patients receiving standard doses of ivermectin and we compared clinical and microbiological outcomes with a similar group of patients not receiving ivermectin. No differences were found between groups. We recommend the evaluation of high-doses of ivermectin in randomized trials against SARS-CoV-2.